Key Takeaways
Belite Bio (NASDAQ: BLTE) reported a first-quarter adjusted loss of $0.34 per share, significantly beating analyst forecasts for a loss of $0.64, as the company pushes forward with its submission to U.S. regulators for its lead drug candidate.
"This has been an exciting start to the year for Belite. In April, we announced the initiation of our rolling NDA submission to the FDA for tinlarebant in STGD1, an important step on our path to becoming a commercial company," Dr. Tom Lin, Chairman and CEO of Belite Bio, said in a statement.
The clinical-stage biotech company posted a GAAP net loss of $26.9 million, or $0.68 per share, compared to a net loss of $14.3 million in the same period last year. The wider loss was driven by increased spending on clinical trials and preparations for a potential commercial launch. The company ended the quarter with $798.6 million in cash and equivalents.
The results come as Belite Bio advances its rolling New Drug Application (NDA) to the U.S. Food and Drug Administration for tinlarebant, a potential first-ever treatment for Stargardt disease (STGD1), a rare genetic eye disease that causes vision loss. The company expects to complete the submission in the second quarter of 2026.
Belite Bio is actively preparing for a potential U.S. launch of tinlarebant, having filled all key commercial leadership positions and building out its sales and medical affairs teams. During the earnings call, management outlined a plan for a 30 to 40-person commercial team.
The company is also pursuing approval in Japan, where tinlarebant has Sakigake (Pioneer Drug) Designation. Enrollment for its DRAGON II trial, which is intended to facilitate approval in Japan, was completed in March with 73 subjects. Management expects a decision from Japanese regulators within three months of any FDA approval.
Research and development expenses for the first quarter rose to $15.7 million from $9.4 million a year earlier, while selling, general and administrative costs increased to $17.0 million from $6.1 million. The increases were attributed to the DRAGON II trial, drug manufacturing, and team expansion.
Despite the higher cash burn, Chief Financial Officer Hao-Yuan Chuang noted the company's strong capital position. "We are sitting on close to $800 million in cash," Chuang said on the call, stating the company is in a "very, very comfortable cash position" to fund the U.S. launch and its existing pipeline, with a total projected budget of around $450 million.
The positive results and regulatory progress reduce the risk for Belite Bio as it transitions toward becoming a commercial-stage company. Investors will be closely watching for the completion of the NDA submission by the end of the second quarter and any subsequent updates from the FDA.
This article is for informational purposes only and does not constitute investment advice.
